SCHEMBL2201682

SCHEMBL2201682

COC(=O)c1cnc2c(O)cccc2c1

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PSMD14 O00487 4/20 0.70
KDM4E B2RXH2 7/20 0.55
HPGDS O60760 1/20 0.53
ALOX15 P16050 1/20 0.49
HTT P42858 1/20 0.49
STAMBP O95630 3/20 0.48
COPS5 Q92905 2/20 0.48
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA7 P43166 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
PAX8 Q06710 1/20 0.47
MAPK1 P28482 1/20 0.45
XDH P47989 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20605105 0.85 PSMD14 (0.70) PSMD14KDM4EHPGDSALOX15HTT
SCHEMBL2201187 0.84 KDM4E (0.55) PSMD14KDM4ECA12CA1CA2
SCHEMBL24801292 0.84 PSMD14 (0.68) PSMD14KDM4EHPGDSALOX15HTT
SCHEMBL2200731 0.84 HPGDS (0.75) PSMD14KDM4EHPGDSALOX15HTT
SCHEMBL2204711 0.81 PSMD14 (0.67) PSMD14KDM4ESTAMBPCOPS5PAX8
SCHEMBL17375869 0.81 PSMD14 (0.64) PSMD14KDM4EHPGDSALOX15HTT
SCHEMBL27994689 0.81 PSMD14 (0.64) PSMD14KDM4EHPGDSALOX15HTT
SCHEMBL2033745 0.80 PSMD14 (0.68) PSMD14KDM4ESTAMBPCOPS5PAX8
SCHEMBL30643089 0.80 PSMD14 (0.68) PSMD14KDM4ESTAMBPCOPS5PAX8
Hydrochloric Acid SCHEMBL16027160 0.80 PSMD14 (0.65) PSMD14KDM4ESTAMBPCOPS5PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1868998-B1 NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS VFP THERAPIES (FR) 2016-05-25 EP disclosed
US-7977354-B2 Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents INSA ROUEN (FR) 2011-07-12 US disclosed
US-20090062279-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS INSA ROUEN (FR) 2009-03-05 US disclosed
EP-1868998-A2 NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS Insa Rouen (FR) 2007-12-26 EP disclosed
WO-2006103120-A2 NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS INSA ROUEN (FR) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062279-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS NLN, SNCA, APP PSMD14 2227/4885KDM4E 1927/4885HPGDS 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.